Based on the BioCryst Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for BioCryst Pharmaceuticals Inc is not available over the next 12 months. BioCryst Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioCryst Pharmaceuticals Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, BioCryst Pharmaceuticals Inc’s stock price was EUR 7.34. BioCryst Pharmaceuticals Inc’s stock price has changed by -3.42% over the past week, -3.06% over the past month and +52.73% over the last year.
No recent analyst target price found for BioCryst Pharmaceuticals Inc
No recent average analyst rating found for BioCryst Pharmaceuticals Inc
Company Overview BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Read Less
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPI...Read More
Frequently Asked Questions About BioCryst Pharmaceuticals Inc (BO1:F) Stock
Stock Target Advisor's fundamental analysis for BioCryst Pharmaceuticals Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on BO1:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BO1:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BO1:F's stock to indicate if its overvalued.
The last closing price of BO1:F's stock was EUR 7.34.
The most recent market capitalization for BO1:F is EUR 1.56B.
Unfortunately we do not have enough analyst data on BO1:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BioCryst Pharmaceuticals Inc's stock.
As per our most recent records BioCryst Pharmaceuticals Inc has 536 Employees.
BioCryst Pharmaceuticals Inc's registered address is 4505 Emperor Boulevard, Durham, NC, United States, 27703.
You can get more information about it from BioCryst Pharmaceuticals Inc's website at https://www.biocryst.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About BioCryst Pharmaceuticals Inc (BO1:F) Stock
Stock Target Advisor's fundamental analysis for BioCryst Pharmaceuticals Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on BO1:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BO1:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BO1:F's stock to indicate if its overvalued.
The last closing price of BO1:F's stock was EUR 7.34.
The most recent market capitalization for BO1:F is EUR 1.56B.
Unfortunately we do not have enough analyst data on BO1:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BioCryst Pharmaceuticals Inc's stock.
As per our most recent records BioCryst Pharmaceuticals Inc has 536 Employees.
BioCryst Pharmaceuticals Inc's registered address is 4505 Emperor Boulevard, Durham, NC, United States, 27703.
You can get more information about it from BioCryst Pharmaceuticals Inc's website at https://www.biocryst.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BO1:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
